Biodeal Pharmaceuticals Concludes ₹110 Crore Piramal Alternatives Investment with 20%+ IRR

Biodeal Pharmaceuticals has successfully concluded its investment partnership with Piramal Alternatives, following the full redemption of the ₹110 crore investment made by Piramal Structured Credit Opportunities Fund in 2024. The investment generated an internal rate of return (IRR) of over 20%, marking a successful conclusion to a partnership focused on accelerating business growth, strengthening operational capabilities and building a stronger institutional foundation.

The partnership represents an important milestone in Biodeal Pharmaceuticals’ growth journey and reflects the company’s continued progress across financial performance, manufacturing capabilities, governance and operational excellence.

Strong Business Growth During the Partnership

During the investment period, Biodeal Pharmaceuticals delivered significant business growth while strengthening operational efficiency.

The company recorded 45% year-on-year revenue growth in FY25, followed by a further 60% growth in FY26. Alongside this strong expansion, Biodeal also achieved a significant improvement in its EBITDA margin, reflecting increased operational efficiencies and disciplined business execution.

The company’s performance during this period demonstrates its ability to scale its pharmaceutical manufacturing and formulation capabilities while maintaining a strong focus on quality, compliance and sustainable growth.

Strengthening Pharmaceutical Manufacturing Capabilities

Beyond financial performance, the partnership supported Biodeal Pharmaceuticals in strengthening its long-term operational and institutional capabilities.

During the partnership, the company focused on:

·         Expanding manufacturing capabilities

·         Strengthening governance frameworks

·         Improving operational discipline

·         Investing ahead of business demand

·         Expanding its product portfolio

·         Enhancing formulation development capabilities

·         Building capabilities to serve domestic and international markets

These initiatives have helped establish a stronger platform for Biodeal’s next phase of growth as a pharmaceutical manufacturing and formulation partner.

Piramal Alternatives’ Investment and Successful Exit

Piramal Alternatives invested ₹110 crore in Biodeal Pharmaceuticals in 2024 through its Piramal Structured Credit Opportunities Fund. The investment was made as part of the fund’s strategy of supporting high-growth healthcare and pharmaceutical businesses with strong fundamentals and scalable business models.

Following the full redemption of the investment, the fund achieved an IRR of over 20%.

Commenting on the partnership, Kalpesh Kikani, Managing Director & CEO, Piramal Alternatives, said:

“Our investment in Biodeal was anchored in a simple thesis: back a differentiated pharmaceutical platform with a leadership position in nasal formulation and a strong promoter capable of scaling the business profitably.”

He further highlighted Biodeal’s significant revenue and EBITDA growth, expansion of its product portfolio, and strengthening presence across domestic and export markets.

A Transformational Partnership for Biodeal Pharmaceuticals

For Biodeal Pharmaceuticals, the partnership extended beyond growth capital. It provided an opportunity to strengthen the company’s governance, operational systems and long-term growth foundation.

Anurag Kumar, Chairman & Managing Director, Biodeal Pharmaceuticals, said:

“Our partnership with Piramal Alternatives has been transformational. Beyond providing growth capital, they encouraged us to strengthen governance, invest ahead of demand, enhance operational discipline and build a stronger foundation for sustainable growth.”

He also acknowledged the contribution of the Biodeal team and its commitment to delivering strong business performance throughout the partnership.

Expanding Global Pharmaceutical Capabilities

Today, Biodeal Pharmaceuticals serves customers across multiple global markets and continues to focus on quality, compliance and innovation.

With growing capabilities in pharmaceutical formulation development and manufacturing, the company remains focused on strengthening its position as a trusted pharmaceutical partner for domestic and international customers.

The successful conclusion of the Piramal Alternatives partnership provides another important milestone as Biodeal moves into its next phase of growth.

Biodeal Pharmaceuticals’ Next Phase of Growth

Following the successful completion of the partnership, Biodeal Pharmaceuticals remains focused on building a future-ready pharmaceutical business through continued investments in:

·         Manufacturing excellence

·         Pharmaceutical formulation development

·         Product and technology capabilities

·         Operational efficiency

·         Quality and compliance

·         Innovation

·         Domestic and international market expansion

The company will continue to build on the momentum created over the past two years while focusing on long-term value creation for customers, partners, employees and other stakeholders.

About Biodeal Pharmaceuticals

Biodeal Pharmaceuticals is a pharmaceutical company focused on formulation development and manufacturing, with capabilities serving both domestic and international markets. The company is committed to quality, compliance, innovation and manufacturing excellence as it continues to expand its pharmaceutical capabilities and global presence

"This announcement has been covered by:"
* [The Hindu Business Line] — [Click Here]
* ⁠[Express Pharma] — [lClick Here]

* ⁠[Hindustan Times] — [Click Here]

* ⁠[ANI News] — [Click Here]